To include your compound in the COVID-19 Resource Center, submit it here.

Sunesis falls on delay for vecabrutinib readout

Sunesis Pharmaceuticals Inc. (NASDAQ:SNSS) was off $3.12 (43%) to $4.24 on Friday after disclosing that a data readout from the dose-escalation Phase Ib portion

Read the full 246 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE